Trauma-focused therapy can be delivered safely and effectively for people with psychosis
For decades, people living with both psychosis and post-traumatic stress were quietly excluded from the treatments most likely to help them — not because evidence said it was unsafe, but because clinicians assumed it would be. A landmark UK trial has now tested that assumption at scale and found it wanting, demonstrating that integrated trauma-focused therapy can meaningfully relieve suffering in one of mental healthcare's most overlooked populations. The finding is less a discovery than a correction — a long-overdue reckoning with the harm that untested caution can quietly sustain.
- People with psychosis experience PTSD at five times the rate of the general population, yet have been systematically shut out of trauma therapy for generations based on fear rather than evidence.
- The STAR trial — 305 participants, five UK sites, five years — directly challenged that exclusion by testing an integrated therapy combining trauma-focused work with cognitive behavioral approaches for psychosis.
- Half of those who completed the nine-month treatment no longer met PTSD criteria, compared to just one in five receiving standard care, with a strikingly low 6.5% dropout rate signaling genuine patient engagement.
- Improvements cascaded across 22 of 27 measured outcomes, including reductions in paranoia, hallucinations, depression, anxiety, and suicidal ideation — suggesting the two conditions are far more intertwined than clinical practice had acknowledged.
- The trial's authors and participants are now pressing for policy change, arguing that the evidence demands mental health systems dismantle the structural exclusions that have prolonged unnecessary suffering.
For decades, people living with psychosis who also carried the weight of post-traumatic stress disorder were quietly told there was nothing to be done. Clinicians feared that confronting trauma directly might destabilize their patients further — worsening delusions, intensifying hallucinations — and so these individuals were excluded from nearly every research trial on trauma therapy. They were left to manage two intertwined conditions as though they were separate, or not at all.
The STAR trial, led by researchers at King's College London and published in The Lancet Psychiatry, set out to test whether that fear had any basis. Across five UK sites, 305 participants received either an integrated nine-month therapy — weaving trauma-focused work together with cognitive behavioral therapy for psychosis — or standard care. The results were clear: half of those in the therapy group no longer met the diagnostic criteria for PTSD by the end of treatment, compared to just over one in five in the comparison group. The dropout rate of 6.5% was exceptionally low, suggesting the approach was not only effective but genuinely acceptable to people long deemed unsuitable for such treatment.
The significance runs deeper than the numbers. PTSD and psychosis are not neatly separate in lived experience — traumatic memories become entangled with delusions and hallucinations, shaping their content and emotional force. The trial's integrated approach addressed this directly, and improvements extended well beyond PTSD: across 27 measured outcomes, participants showed meaningful gains in 22, including reductions in paranoia, depression, anxiety, and suicidal ideation.
Professor Emmanuelle Peters, who led the study, credited the therapy's success to direct engagement with trauma memory, sustained patient focus, and individualized flexibility. One participant, Shane, now works as a peer-support worker at the clinic where the therapy is delivered, describing it as giving him tools to make sense of accumulated trauma and reclaim a sense of control. His story echoes what the data suggests: that many others found similar value in finally being offered care they had long been denied.
The researchers are now calling for the findings to reshape policy and service delivery — not just clinical practice, but the underlying assumptions of mental health systems that have treated exclusion as a form of protection. The science now makes clear it was neither.
For decades, people with psychosis who also suffered from post-traumatic stress disorder were told, in effect, that they could not be helped. Clinicians feared that talking directly about trauma—the standard treatment for PTSD—would destabilize their patients' grip on reality, making delusions and hallucinations worse. So these patients were excluded from nearly every research trial designed to test trauma therapy. They were left to manage both conditions separately, or not at all.
A five-year study led by researchers at King's College London has upended that assumption. The STAR trial, published in The Lancet Psychiatry, recruited 305 participants across five UK sites and tested an integrated approach: trauma-focused therapy woven together with cognitive behavioral therapy for psychosis. The results were unambiguous. Half the people who received the nine-month treatment no longer met the diagnostic criteria for PTSD when it ended. In the comparison group receiving standard care, only just over one in five achieved that outcome. The dropout rate was exceptionally low at 6.5 percent, suggesting the therapy was not only effective but acceptable to patients who had previously been written off as unsuitable candidates.
The stakes of this finding are substantial. PTSD occurs in people with psychosis at rates five times higher than in the general population. The two conditions are not separate in their lived experience—traumatic memories become woven into delusions and hallucinations, shaping their content and intensity. A person might experience both intrusive flashbacks and paranoid beliefs rooted in the same traumatic event. Until now, mental health services had no evidence-based way to address both at once.
Professor Emmanuelle Peters, who led the study, emphasized that the therapy's success rested on three elements: direct work with the trauma memory itself, sustained focus on keeping patients engaged, and flexibility tailored to each person's needs. The results extended beyond PTSD symptom reduction. Across 27 measured outcomes, participants showed significant improvement in 22 of them, including reductions in paranoia, hallucinations, depression, anxiety, and suicidal ideation. The effect sizes ranged from moderate-to-large on the primary outcome down to small but meaningful gains across other domains of psychological functioning.
What makes this particularly significant is what it corrects. For generations, people with psychosis were systematically excluded from trauma-focused research and treatment—not because the science showed it was dangerous, but because clinicians assumed it would be. That assumption was never tested at scale. The STAR trial tested it rigorously, and the assumption collapsed. Dr Amy Hardy, a joint author of the study, called the findings a challenge to "a longstanding gap in mental healthcare," one that had denied access to evidence-based care to a population already marginalized by stigma and complexity.
One participant in the trial, a man named Shane, now works as a peer-support worker at the PICuP Clinic where the therapy is delivered. He described the experience as giving him tools to make sense of years of accumulated trauma, to rebuild trust and confidence, and to recover a sense of control. He is not alone in that experience—the low dropout rate and high engagement suggest many others found similar value. The clinic, based at South London and Maudsley NHS Foundation Trust, now trains clinicians in the integrated approach and has begun delivering it to new patients.
The question now is whether this evidence will reshape policy and practice. The researchers hope the STAR trial becomes what they call a "gamechanger," motivating commissioners and services to prioritize implementation of trauma-focused therapy for people with psychosis. That would require not just clinical adoption but a shift in how mental health systems think about complex, overlapping diagnoses. It would mean recognizing that exclusion itself can be a form of harm—that silence imposed by lack of access perpetuates suffering in people who have already endured trauma. The science now supports a different path.
Citas Notables
It is now clear that trauma-focused therapies can be delivered safely and effectively for people with PTSD and psychosis. This intervention, which includes working on the trauma memory directly, a focus on engagement, and a flexible approach tailored to the individual, is safe, highly acceptable and effective.— Professor Emmanuelle Peters, study lead
STAR therapy gave me the tools to make sense of experiences I had carried for years and change how I see myself and others. It gave me back a feeling of control and the belief that recovery is possible.— Shane, trial participant and peer-support worker
La Conversación del Hearth Otra perspectiva de la historia
Why were people with psychosis excluded from trauma therapy for so long? Was there evidence it made things worse?
No—that's the striking part. It was assumption, not evidence. Clinicians feared that talking directly about trauma would destabilize psychosis symptoms, but that fear was never tested at scale. It became received wisdom without a rigorous trial to back it up.
So the STAR trial was essentially testing whether that fear was justified?
Exactly. They brought 305 people with both diagnoses into a structured nine-month therapy that worked directly with trauma memories. If the fear was right, you'd expect higher dropout rates, worse psychosis outcomes, maybe crisis episodes. Instead, dropout was only 6.5 percent and outcomes improved across the board.
What does "integrated" mean in this context? Why not just give them standard PTSD therapy?
Because psychosis changes how trauma presents itself. Traumatic memories don't just come back as flashbacks—they get woven into delusions and hallucinations. The therapy had to address both simultaneously, using cognitive behavioral techniques designed for psychosis while also processing the trauma directly.
Half the people no longer met PTSD criteria. What about the other half?
They still improved significantly. The study measured 27 different outcomes—paranoia, hallucinations, depression, anxiety, suicidal ideation. Even people who still had some PTSD symptoms showed meaningful gains across those other domains. Recovery isn't binary.
Why does this matter beyond the clinical numbers?
Because these are people who were told they couldn't be helped. Systematically excluded from research and treatment. The message was: your condition is too complicated, too risky. Now there's evidence that's wrong. That's not just a clinical finding—it's an ethical one.
What happens next?
That depends on whether health systems actually implement this. The researchers hope it becomes a priority for commissioners and services. But evidence alone doesn't guarantee change. There has to be will to overturn decades of exclusionary practice.